Skip to main content
. 2021 Nov 24;24(3):513–525. doi: 10.1002/ejhf.2381

Figure 2.

EJHF-2381-FIG-0002-c

Cumulative incidence of new‐onset atrial fibrillation in dapagliflozin according to randomized treatment assignment in patients without atrial fibrillation (history or baseline electrocardiogram). Cumulative incidence of new‐onset atrial fibrillation was estimated using the Aalen–Johansen estimator, taking the competing risk of death into account.